

Please add the following new claims:

40 (new). The antibody of claim 18 in which said antigen administered to said antibody-producing animal includes a peptide comprising a sequence of at least 16 amino acids in length from SEQ ID NO:2.

C4 41 (new). The antibody of claim 18 or claim 19 in which the antibody selectively inhibits the serine protease activity of MASP-2.

42 (new). The antibody of claim 18 or claim 19 in which the antibody selectively binds to the serine protease domain of SEQ ID NO:2.

43 (new). The antibody of claim 18 or claim 19 in which the antibody inhibits MASP-2 catalyzed cleavage of complement factor C2 or C4.

REMARKS

The purpose of this amendment is to better claim the invention (18, 40-43) to correct a typographical error (22), and to redefine claim 37 so it can be rejoined herewith under MPEP §821.04.

Please note that a substitute power of attorney, including a change of correspondence address was filed October 21, 2002.

On June 4, 2001 Fish & Richardson (original counsel for applicant) paid the basic filing fee for the above-identified application. However, at the time of filing no fees were expressly paid for independent claims in excess of 3 or multiple dependent claims. We assume that Fish & Richardson's PTO Deposit Account was charged for these fees. However, if our assumption is not correct, please charge our PTO Deposit Account No. 02-4035 the fee of \$180.00 (multiple dependent claims fee \$140.00 and 1 extra independent claim \$40).

USSN - 09/874,238

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: 

Iver P. Cooper
Reg. No. 28,005

624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
IPC:lms
G:\BN\H\hoib\Jensenius3B\ptothirdpreamend.wpd

RECEIVED

NOV 01 2002

TECH CENTER 1600/2900

USSN - 09/874,238



VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

Claims 18, 22 and 37 have been amended as follows:

18 (twice amended). An antibody produced by administering an antigen comprising a mannin-binding lectin associated serine protease-2 MASP-2 polypeptide to an antibody producing animal.

22 (twice amended). A pharmaceutical composition comprising [or] the antibody of claims 18 or 19.

37 (amended). A method for diagnosing a disorder associated with aberrant expression of MASP-2, comprising obtaining a biological sample from a patient and measuring MASP-2 expression in said biological sample, wherein increased or decreased MASP-2 expression in said biological sample compared to a control indicates that said patient suffers from a disorder associated with aberrant expression of MASP-2, where MASP-2 expression is measured by means of an assay reagent comprising an antibody according to claim 18 or claim 19.

Claims 40-43 have been added.